Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.48 |
| ▸ | EBP | Q15125 | 8/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 9/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 9/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795762 | 0.86 | NR1H3 (0.39) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL14976244 | 0.85 | HMGCR (0.49) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL20552574 | 0.85 | HMGCR (0.50) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL23795763 | 0.79 | HMGCR (0.47) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL20003472 | 0.78 | PRKAG1 (0.50) | HMGCRPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL4957748 | 0.78 | HMGCR (0.55) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL1525597 | 0.77 | HMGCR (0.47) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL4157317 | 0.75 | HMGCR (0.46) | HMGCREBPPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL4146623 | 0.74 | EBP (0.46) | HMGCREBP | |
| SCHEMBL16533990 | 0.74 | HMGCR (0.45) | HMGCREBPPRKAG1PRKAA2PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240222-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240218402-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2024-07-04 | — | — | US | disclosed |
| US-20240218414-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2024-07-04 | — | — | US | disclosed |
| EP-4314316-A2 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | Firmenich Incorporated (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023278976-A2 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4077649-A1 | MICROBIAL PRODUCTION OF MOGROL AND MOGROSIDES | Manus Bio Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20210324439-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2021-10-21 | — | — | US | disclosed |
| EP-3877519-A1 | BIOSYNTHESIS OF MOGROSIDES | Ginkgo Bioworks, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3860364-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | Firmenich Incorporated (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860363-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | Firmenich Incorporated (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11060124-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021126960-A1 | MICROBIAL PRODUCTION OF MOGROL AND MOGROSIDES | Manus Bio, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021081327-A1 | BIOSYNTHESIS OF MOGROSIDES | GINKGO BIOWORKS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3615679-A2 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | Firmenich Incorporated (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190071705-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2019-03-07 | — | — | US | disclosed |
| WO-2018204483-A2 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | SENOMYX, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210324439-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | OXER1, MAN1B1, GMDS | HMGCR 2204/4885EBP 945/4885PRKAG1 1166/4885 |
| US-11060124-B2 | Methods for making high intensity sweeteners | OXER1, MAN1B1, GMDS | HMGCR 2204/4885EBP 945/4885PRKAG1 1166/4885 |
| US-20190071705-A1 | METHODS FOR MAKING HIGH INTENSITY SWEETENERS | OXER1, MAN1B1, GMDS | HMGCR 2204/4885EBP 945/4885PRKAG1 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.